Author/Editor     Čufer, Tanja; Knez, Lea
Title     Update on systemic therapy of advanced non-small-cell lung cancer
Type     članek
Vol. and No.     Letnik 14, št. 10
Publication year     2014
Volume     str. 1189-1203
ISSN     1473-7140 - Expert review of anticancer therapy
Language     eng
Abstract     In the last decade, major progress in the treatment of advanced non-small-cell lung cancer has been made through the better understanding of the molecular biology of lung cancer, identification of new oncogene drivers and development of oncogene-directed drugs. Oncogene-directed therapies with EGFR or anaplastic lymphoma kinase tyrosine kinase inhibitors became standard practice in patients with activating EGFR mutations or anaplastic lymphoma kinase rearrangements, improving median survival rates to up to 35 months. Encouragingly, there are still numerous other targeted drugs and treatment strategies under development. In addition, nowadays chemotherapy can be tailored based on histology of the primary tumor and response to induction chemotherapy, raising median survival rates up to 13 months. These major developments, both in oncogene- and non-oncogene-directed therapies is presented in this review, together with a further designation of the most relevant future strategies, such as immunotherapy.
Keywords     napredovali rak
nedrobnocelični rak
rak pljuč
sistemska terapija
advanced disease
non-oncogene-directed therapies
non-small-cell lung cancer
oncogene-directed therapies